Firm Analyst
Canaccord Genuity John Newman, Ph.D.
Cowen and Company Phil Nadeau, Ph.D.
Guggenheim Securities William Tanner, Ph.D.
ISI Group Mark Schoenebaum, M.D.
J.P. Morgan Cory Kasimov
Leerink Swann Paul Matties
MLV & Co. Ram Selvaraju, Ph.D.
Piper Jaffray Co. Traver Davis
RBC Capital Markets Michael Yee
Stifel Nicolaus Thomas Shrader

Acorda Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Acorda Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Acorda Therapeutics, Inc. or its management. Acorda Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Stock Quote

ACOR (Common Stock) $ 34.21 +0.43 (+1.27%) Volume: 693,762 MORE July 30, 2015

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *